Imipramine

Introduction Overview

Generic Name

imipramine

Brand Name

Tofranil, Tofranil-PM

Dosage Form

oral capsule (pamoate 75 mg; 100 mg; 125 mg; 150 mg), oral tablet (10 mg; 25 mg; 50 mg)

Drug Class

Tricyclic antidepressants

Pharmacokinetics

Absorption:
Imipramine is administered orally, and its absorption occurs primarily through the gastrointestinal tract, chiefly in the small intestine. The drug exhibits fairly good oral bioavailability, although it undergoes significant first-pass metabolism in the liver, which can reduce the fraction reaching systemic circulation. The rate of absorption can be influenced by factors such as gastric pH and the presence of food, but food does not significantly affect the extent of absorption. Peak plasma concentrations are typically reached within 2 to 6 hours post-dose. Variability exists between individuals, affected by age, gastrointestinal motility, and hepatic blood flow.

Distribution:
Once absorbed, imipramine is widely distributed throughout body tissues, with high affinity for adipose tissue and the central nervous system due to its lipophilic properties. It crosses the blood-brain barrier effectively, which underlies its central nervous system effects. Imipramine also crosses the placental barrier and is found in breast milk, implying potential exposure to fetus and nursing infants. Approximately 90-95% of circulating imipramine binds to plasma proteins, primarily albumin, which modulates its free active concentration. The volume of distribution (Vd) is large, estimated between 10 to 20 L/kg, indicating extensive tissue uptake.

Metabolism:
Imipramine is extensively metabolized in the liver via the cytochrome P450 enzyme system, particularly CYP2D6, CYP1A2, and CYP3A4 isoenzymes. It undergoes N-demethylation to form desipramine, an active metabolite with antidepressant activity and a pharmacologic profile similar to the parent drug. Further metabolism includes hydroxylation, conjugation, and oxidation processes. The metabolic pathways exhibit genetic polymorphism, meaning that poor or extensive metabolizers of CYP2D6 substrates can have notable differences in plasma drug levels, efficacy, and risk of adverse effects. Drug interactions impacting these metabolic enzymes can significantly alter imipramine metabolism.

Elimination:
Elimination occurs primarily via renal excretion of metabolites and to a lesser extent via feces. Only trace amounts of unchanged imipramine are excreted in urine. The elimination half-life of imipramine ranges from 8 to 24 hours, but can be prolonged in elderly patients, those with hepatic impairment, or CYP2D6 poor metabolizers. Steady-state plasma concentrations are reached within approximately one to two weeks of consistent dosing. The pharmacokinetic profile supports once or twice-daily dosing regimens. Renal or hepatic dysfunction may necessitate dose adjustments due to altered elimination and accumulation risk.

Dosage Forms

Available Dosage Forms:
Imipramine is available in both oral capsule and oral tablet formulations.
- Oral capsule (imipramine pamoate): 75 mg, 100 mg, 125 mg, 150 mg
- Oral tablet: 10 mg, 25 mg, 50 mg

Dosages for Adults and Adolescents:
For depression treatment, initial dosing typically starts at 75 mg per day, divided into one or two doses. The daily dose can be gradually increased as tolerated up to a maximum of 200 mg per day. Dosage adjustments are individualized based on clinical response and side effect profile. Maintenance doses often range between 50 mg to 150 mg daily.
For enuresis (bed-wetting) in children aged 6 years and older, dosing usually begins at lower levels, such as 25 mg at bedtime, with subsequent adjustment depending on therapeutic response and tolerability. Imipramine is not approved for depression treatment in children under 18 years old.

Specific Patient Populations:
Elderly patients may require lower initial doses due to increased sensitivity and altered metabolism. Those with hepatic or renal impairment also warrant cautious dosing and careful monitoring as drug clearance may be reduced. Patients with cardiac disease require special consideration because imipramine can have cardiotoxic effects. Children under 6 years of age should not use imipramine for enuresis due to safety concerns. Breastfeeding is generally contraindicated during imipramine therapy due to drug excretion into breast milk. In pregnancy, use is only recommended if potential benefits justify the risks.

Clinical guidelines recommend gradual titration and cautious dose adjustments to minimize adverse effects while achieving therapeutic efficacy. Regular assessment of clinical response and adverse reactions is vital in all patient groups.

Mechanism Of Action

Imipramine primarily acts as a tricyclic antidepressant by inhibiting the reuptake of neurotransmitters norepinephrine (NE) and serotonin (5-HT) at presynaptic nerve terminals. By blocking the norepinephrine transporter (NET) and serotonin transporter (SERT), it elevates synaptic concentrations of these monoamines in the central nervous system, which ameliorates depressive symptoms and improves mood regulation. This dual reuptake inhibition distinguishes imipramine from some other TCAs which may selectively favor norepinephrine.

At the cellular level, imipramine modulates neuronal signaling pathways by increasing neurotransmitter levels in critical brain regions such as the locus coeruleus, raphe nuclei, and limbic structures implicated in mood, anxiety, and sleep regulation. This neurotransmitter imbalance correction enhances postsynaptic receptor activation, promoting neuroplasticity and improved neuronal communication over time. Imipramine can also antagonize several receptors including muscarinic cholinergic, histaminergic (H1), and alpha-1 adrenergic receptors, underlying many of its side effects such as anticholinergic symptoms, sedation, and orthostatic hypotension.

Biochemically, imipramine's inhibition of monoamine reuptake leads to downstream modulation of second messenger systems, including cyclic AMP and protein kinase activation, which may contribute to long-term changes in gene expression and neuronal survival. These mechanisms are thought to underlie the delayed onset of clinical antidepressant effects commonly observed during treatment.

Clinically, imipramine has demonstrated efficacy in treating major depressive disorder and nocturnal enuresis in children, reflecting its modulatory effects on central nervous system pathways involved in mood regulation and bladder control. Compared to selective serotonin reuptake inhibitors (SSRIs), imipramine's broader neurotransmitter reuptake inhibition and receptor antagonism result in a different side effect profile and efficacy spectrum. Research evidence from clinical trials and neuropharmacological studies supports imipramine’s role as a foundational agent in antidepressant pharmacotherapy with recognized benefits and risks.

Pharmacological Actions

Inhibits presynaptic reuptake of norepinephrine and serotonin, increasing their synaptic availability.
Blocks muscarinic cholinergic receptors causing anticholinergic effects such as dry mouth and blurred vision.
Antagonizes histamine H1 receptors leading to sedation and potential weight gain.
Blocks alpha-1 adrenergic receptors resulting in vasodilation and orthostatic hypotension.
Exerts antidepressant effects by enhancing neurotransmission in mood-regulating brain pathways.
Demonstrates anxiolytic properties through modulation of serotonergic and noradrenergic systems.
Reduces symptoms of nocturnal enuresis likely via anticholinergic and central nervous system effects.
Alters cardiac conduction by affecting sodium channels, which can lead to arrhythmias in overdose.
Modifies neuronal signal transduction pathways contributing to long-term therapeutic effects.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder in adults.
Management of enuresis (bed-wetting) in children aged 6 years and older.
Off-label use in some anxiety disorders due to anxiolytic properties.
Adjunctive therapy for chronic pain syndromes, leveraging neuromodulatory effects.
May be employed in treatment-resistant depression where other agents are ineffective.
Sometimes utilized in off-label capacity for panic disorder.
Used to improve sleep disturbances associated with depression due to sedative effects.
Treatment for certain types of neuropathic pain through central nervous system action.
Management of agitated depression due to calming receptor antagonism effects.

Side Or Adverse Effects

Dry mouth due to anticholinergic activity.
Drowsiness or sedation especially at treatment initiation.
Orthostatic hypotension causing dizziness or light-headedness.
Increased heart rate (tachycardia) and palpitations.
Weight gain associated with histamine H1 antagonism.
Blurred vision resulting from anticholinergic effects.
Constipation due to decreased gastrointestinal motility.
Difficulty urinating secondary to anticholinergic mechanisms.
Confusion or cognitive impairment, particularly in elderly patients.
Sexual dysfunction including decreased libido and erectile difficulties.
Increased risk of seizures, especially in predisposed individuals.
Photosensitivity leading to increased susceptibility to sunburn.
Potential hepatotoxicity manifesting as jaundice in rare cases.
Cardiac conduction abnormalities such as QT prolongation and arrhythmias.
Risk of suicidal thoughts or behavior, particularly in young adults and adolescents.

Precautions

Use cautiously in patients with a history of cardiovascular disease due to risk of arrhythmias.
Monitor elderly patients closely for increased sensitivity and cognitive impairment.
Avoid abrupt discontinuation to prevent withdrawal symptoms; taper doses gradually.
Use with caution in individuals with a seizure history as imipramine may lower seizure threshold.
Assess for bipolar disorder prior to initiation, as antidepressants can induce mania.
Avoid concurrent use with monoamine oxidase inhibitors due to risk of hypertensive crisis.
Adjust dose in hepatic or renal impairment to avoid toxicity from reduced clearance.
Monitor blood pressure regularly due to risk of orthostatic hypotension.
Counsel patients regarding photosensitivity and recommend sun protection measures.
Advise against alcohol consumption as it enhances CNS depressant effects.
Be vigilant for worsening depression or emergence of suicidal ideation, especially in young adults.
Use caution with other medications that cause sedation or anticholinergic side effects.
Pregnancy and breastfeeding considerations require weighing potential benefits against risks.
Children under 6 years should not receive imipramine for enuresis due to safety concerns.
Inform patients about the potential for impaired judgment or delayed reaction time.

Warnings

Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
Potential for fatal overdose, particularly due to cardiotoxicity and seizures.
Serious cardiac arrhythmias may occur, especially in overdose or in patients with pre-existing heart conditions.
Do not use simultaneously with or within 14 days of discontinuing MAO inhibitors due to risk of serotonin syndrome.
Use during pregnancy should only occur if clearly needed due to unknown potential fetal risks.
Associated with anticholinergic toxicity, especially in elderly or overdose scenarios.
May cause confusion, hallucinations, and unusual behavior, necessitating careful monitoring.
Risk of severe hypotension during anesthesia; inform anesthesiologist if surgery is planned.
Abrupt cessation can precipitate withdrawal symptoms including irritability and sleep disturbances.
Imipramine increases susceptibility to sunburn; exposure should be limited.
Risk of angle-closure glaucoma exacerbation due to anticholinergic effects.
Avoid use in patients with recent myocardial infarction due to increased risk of adverse cardiac events.
Can impair cognitive and motor skills; caution advised when driving or operating machinery.
Potential for interactions leading to serotonin syndrome when combined with other serotonergic agents.
Black box warning for suicide risk mandates close supervision during early therapy phases.

Contraindication

Known hypersensitivity or allergy to imipramine or other tricyclic antidepressants.
Recent myocardial infarction (heart attack) due to increased risk of arrhythmias.
Concurrent or recent (within 14 days) use of monoamine oxidase (MAO) inhibitors.
Use with caution and generally avoided in patients with severe liver impairment.
Patients with untreated narrow-angle glaucoma due to anticholinergic exacerbation risk.
Individuals with known hypersensitivity to related antidepressants such as amitriptyline, desipramine, or clomipramine.
Not approved for use in children under 6 years for enuresis or under 18 years for depression.
Use contraindicated during lactation unless benefits outweigh risks.
Avoid in patients with known seizures uncontrolled by medication due to seizure threshold lowering.
Patients who have shown intolerance to tricyclic antidepressants.

Drug Interactions

Potentially fatal interactions with monoamine oxidase inhibitors (MAOIs).
Increased sedation and CNS depression when combined with alcohol, benzodiazepines, or opioids.
Serotonin syndrome risk when used concomitantly with SSRIs, SNRIs, or other serotonergic drugs.
Enhanced anticholinergic effects when combined with antihistamines or antipsychotics.
CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may elevate imipramine plasma levels increasing toxicity risk.
May reduce effectiveness of antihypertensive drugs due to alpha-adrenergic blockade.
Concomitant use with other QT-prolonging drugs increases risk of cardiac arrhythmias.
Combining with sympathomimetics or vasopressors can cause hypertensive episodes.
Concomitant use with clonidine may lead to unpredictable blood pressure changes.
Use with thyroid medications or anticoagulants may require dose adjustments.
Imipramine can alter plasma levels of carbamazepine and phenytoin, necessitating monitoring.
Combination with alcohol or CNS depressants may impair mental alertness.
Use with tramadol increases risk of seizures and serotonin syndrome.
St. John’s Wort and other herbal supplements can reduce imipramine effectiveness.
MAO inhibitors, linezolid, or methylene blue exposure pose life-threatening interaction risks.

Preparations Of The Drug

Oral capsule containing imipramine pamoate in strengths of 75 mg, 100 mg, 125 mg, and 150 mg.
Oral tablet available in 10 mg, 25 mg, and 50 mg strengths.
Formulations designed for once or twice daily dosing based on clinical indication.
Packaged typically in blister packs or bottles with child-resistant caps.
Prescription-only medication requiring medical supervision for initiation and dose adjustments.
Available as branded products such as Tofranil and Tofranil-PM.
No parenteral or topical formulations are commercially available.
Unsupported for pediatric use in depression but available for enuresis in specific doses.
Stored at room temperature, protected from moisture and light.
Formulations may vary internationally; generic versions are widely available.
Medication guides and patient counseling information accompany prescriptions.
Typically dispensed in standardized fill quantities dictated by prescribing practices.
Pamoate salt form improves drug stability and controlled release characteristics.
Special packaging or labeling may be mandated for safety warnings and administration instructions.
Requires adherence to storage guidelines to maintain drug integrity and efficacy.